The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023 (2024)

Abstract

©
This work is licensed under a Creative Commons Attribution 4.0 International License.

Article metrics loading...

http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.28.2300697

Full text loading...

References

1. Department of Health. Strategic Approach for the Management of COVID-19 Preparedness for Autumn/Winter 2022/2023. Ireland: Department of Health; 2022.

   See Also

   Consumer Insights Tracker Report July 2023 - March 2024: Introduction

2. World Health Organization (WHO). Strategy considerations for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the WHO European Region during autumn and winter 2022/23. Geneva: WHO; 2022.

3. Health Protection Surveillance Centre (HPSC). Summary of COVID-19 virus variants in Ireland, July 2023. Ireland: HPSC; 2023.

4. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. , COVID-19 Genomics UK (COG-UK) consortium. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-12. https://doi.org/10.1016/S0140-6736(22)00462-7PMID: 35305296

5. Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022;22(7):1002-10. https://doi.org/10.1016/S1473-3099(22)00146-3PMID: 35405090

6. National Immunisation Advisory Committee (NIAC). NIAC Immunisation Guidelines: Chapter 5a COVID-19. Ireland: Royal College of Physicians of Ireland; 2023.

7. Government of Ireland. National COVID-19 Vaccination Programme: Strategy. Ireland: Government of Ireland; 2020.

8. European Centre for Disease Prevention and Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. Stockholm: ECDC; 2023.

9. Health Protection Surveillance Centre (HPSC). COVID-19 Vaccination Uptake in Ireland Weekly Report: Week 2 2022. Ireland: HPSC; 2022.

10. National Immunisation Advisory Committee. Additional COVID-19 booster vaccination. Ireland: Royal College of Physicians of Ireland; 2022.

11. European Centre for Disease Prevention and Control (ECDC). Preliminary public health considerations for COVID-19 vaccination strategies in the second half of 2022. Stockholm: ECDC; 2022.

12. European Centre for Disease Prevention and Control (ECDC). Interim public health considerations for COVID-19 vaccination roll-out during 2023. Stockholm: ECDC; 2023.

13. Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effectiveness of Bivalent Boosters against Severe Omicron Infection. N Engl J Med. 2023;388(8):764-6. https://doi.org/10.1056/NEJMc2215471PMID: 36734847

14. Arbel R, Peretz A, Sergienko R, Friger M, Beckenstein T, Duskin-Bitan H, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis. 2023;23(8):914-21. https://doi.org/10.1016/S1473-3099(23)00122-6PMID: 37062302

15. Health Service Executive (HSE) National Immunisation Office. Table of recommended groups for COVID-19 autumn booster and flu vaccine. Ireland: HSE; 2023.

16. Health Protection Surveillance Centre (HPSC). COVID-19 Vaccination Uptake in Ireland Weekly Report: Week 24 2023. Ireland: HPSC; 2023.

17. Health Protection Surveillance Centre (HPSC). COVID-19 Vaccination Uptake in Ireland Weekly Report: Week 16 2023. Ireland: HPSC; 2023.

18. Machado A, Kislaya I, Larrauri A, Matias Dias C, Nunes B. Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population. BMC Public Health. 2019;19(1):1690. https://doi.org/10.1186/s12889-019-7958-8PMID: 31842831

19. Sacco C, Mateo-Urdiales A, Petrone D, Spuri M, Fabiani M, Vescio MF, et al. , Italian Integrated Surveillance of COVID-19 study group. Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January-September 2021. Euro Surveill. 2021;26(47):2101001. https://doi.org/10.2807/1560-7917.ES.2021.26.47.2101001PMID: 34823637

20. Meslé MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. Euro Surveill. 2021;26(47):2101021. https://doi.org/10.2807/1560-7917.ES.2021.26.47.2101021PMID: 34823641

21. Health Service Executive (HSE). Winter Plan October 2022-March 2023. Ireland: HSE; 2022.

22. International Vaccine Access Centre Johns Hopkins Bloomberg School of Public Health and World Health Organisation (WHO) and Coalition for Epidemic Preparedness Innovations. Results of COVID-19 Vaccine Effectiveness & Impact Studies: An Ongoing Systematic Review: Methods. Geneva: WHO; 2023.

23. VIEW-Hub. Available from: https://view-hub.org/resources

24. Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu NC, Chuenkitmongkol S, et al. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Rev Vaccines. 2023;22(1):1-16. https://doi.org/10.1080/14760584.2023.2143347PMID: 36330971

25. Central Statistics Office (CSO). Preliminary Census 2022 results. Dublin: CSO; 2022.

26. R Core Team. (2013). A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.

27. Tamandjou Tchuem CR, Auvigne V, Vaux S, Montagnat C, Paireau J, Monnier Besnard S, et al. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. Vaccine. 2023;41(13):2280-8. https://doi.org/10.1016/j.vaccine.2023.02.062PMID: 36870880

28. Kirsebom FCM, Andrews N, Sachdeva R, Stowe J, Ramsay M, Lopez Bernal J. Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. Nat Commun. 2022;13(1):7688. https://doi.org/10.1038/s41467-022-35168-7PMID: 36509743

29. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1526-30. https://doi.org/10.15585/mmwr.mm7148e1PMID: 36454688

30. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):139-45. https://doi.org/10.15585/mmwr.mm7104e3PMID: 35085224

31. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255-63. https://doi.org/10.15585/mmwr.mm7107e2PMID: 35176007

32. Natarajan K, Prasad N, Dascomb K, Irving SA, Yang DH, Gaglani M, et al. Effectiveness of hom*ologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):495-502. https://doi.org/10.15585/mmwr.mm7113e2PMID: 35358170

33. Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Xie F, et al. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. Lancet Respir Med. 2023;11(2):176-87. https://doi.org/10.1016/S2213-2600(22)00354-XPMID: 36216013

34. Link-Gelles R, Levy ME, Gaglani M, Irving SA, Stockwell M, Dascomb K, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022;71(29):931-9. https://doi.org/10.15585/mmwr.mm7129e1PMID: 35862287

35. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022;379:e072141. https://doi.org/10.1136/bmj-2022-072141PMID: 36191948

36. Link-Gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, et al. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023;6(3):e232598. https://doi.org/10.1001/jamanetworkopen.2023.2598PMID: 36920396

37. Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis. 2022;22(12):1663-5. https://doi.org/10.1016/S1473-3099(22)00692-2PMID: 36306800

38. Bozio CH, Butterfield KA, Briggs Hagen M, Grannis S, Drawz P, Hartmann E, et al. Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance. J Infect Dis. 2023;227(12):1348-63. https://doi.org/10.1093/infdis/jiad040PMID: 36806690

39. Baum U, Poukka E, Leino T, Kilpi T, Nohynek H, Palmu AA. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. BMC Infect Dis. 2022;22(1):816. https://doi.org/10.1186/s12879-022-07814-4PMID: 36335289

40. Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Fafard J, et al. Prior infection- and/or vaccine-induced protection against Omicron BA.1, BA.2 and BA.4/BA.5-related hospitalisations in older adults: a test-negative case-control study in Quebec, Canada. medRxiv: the preprint server for health sciences. 2022:2022.12.21.22283740. https://doi.org/10.1101/2022.12.21.22283740https://doi.org/10.1101/2022.12.21.22283740

41. Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. Nat Commun. 2022;13(1):5736. https://doi.org/10.1038/s41467-022-33378-7PMID: 36180428

42. Sharma A, Oda G, Holodniy M. Effectiveness of Messenger RNA-based Vaccines During the Emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. Clin Infect Dis. 2022;75(12):2186-92. https://doi.org/10.1093/cid/ciac325PMID: 35475889

43. Wan EYF, Mok AHY, Yan VKC, Chan CIY, Wang B, Lai FTT, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. J Travel Med. 2022;29(8):taac119. https://doi.org/10.1093/jtm/taac119PMID: 36250571

44. Young-Xu Y, Zwain GM, Izurieta HS, Korves C, Powell EI, Smith J, et al. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans. BMJ Open. 2022;12(8):e063935. https://doi.org/10.1136/bmjopen-2022-063935PMID: 35922100

45. Gram MA, Emborg HD, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. PLoS Med. 2022;19(9):e1003992. https://doi.org/10.1371/journal.pmed.1003992PMID: 36048766

46. Kislaya I, Machado A, Magalhães S, Rodrigues AP, Franco R, Leite PP, et al. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022. Euro Surveill. 2022;27(37):2200697. https://doi.org/10.2807/1560-7917.ES.2022.27.37.2200697PMID: 36111555

47. Yan VKC, Wan EYF, Ye X, Mok AHY, Lai FTT, Chui CSL, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study. Emerg Microbes Infect. 2022;11(1):2304-14. https://doi.org/10.1080/22221751.2022.2114854PMID: 35980089

48. Park SK, Choe YJ, Jang EJ, Kim RK, Lee SW, Kwon GY, et al. Effectiveness of Heterologous COVID-19 Vaccine Booster in Korean Elderly Population, 2022. J Korean Med Sci. 2023;38(19):e143. https://doi.org/10.3346/jkms.2023.38.e143PMID: 37191847

49. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021;21(11):1529-38. https://doi.org/10.1016/S1473-3099(21)00289-9PMID: 34174193

50. Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R, et al. Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. Lancet Reg Health West Pac. 2023;40:100928. https://doi.org/10.1016/j.lanwpc.2023.100928PMID: 37854458

51. Stamm TA, Partheymüller J, Mosor E, Ritschl V, Kritzinger S, Alunno A, et al. Determinants of COVID-19 vaccine fatigue. Nat Med. 2023;29(5):1164-71. https://doi.org/10.1038/s41591-023-02282-yPMID: 36973410

52. Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, d’Andrea V, et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6(5):e2310650. https://doi.org/10.1001/jamanetworkopen.2023.10650PMID: 37133863

53. European Centre for Disease Prevention and Control (ECDC). Country overview report: week 31 2023. Stockholm: ECDC; 2023.

54. McKeown D, McCourt A, Hendrick L, O’Farrell A, Donohue F, Grabowsky L, et al. COVID-19 incidence and outcome by affluence/deprivation across three pandemic waves in Ireland: A retrospective cohort study using routinely collected data. PLoS One. 2023;18(7):e0287636. https://doi.org/10.1371/journal.pone.0287636PMID: 37478117

55. Department of Health and Health Service Executive. Impact of COVID on the health service. Ireland: Department of Health; 2021.

56. Health Service Executive (HSE). National Adult Critical Care Capacity - Census 2021 Report. Ireland: HSE; 2021.

57. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293-302. https://doi.org/10.1016/S1473-3099(22)00320-6PMID: 35753318

Data & Media loading...